` Comparison: CTKB vs 207940 - Alpha Spread

CTKB
vs
207940

Over the past 12 months, CTKB has underperformed Samsung Biologics Co Ltd, delivering a return of -9% compared to the Samsung Biologics Co Ltd's +75% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
CTKB
207940
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

CTKB Intrinsic Value
4.05 USD
Overvaluation 7%
Intrinsic Value
Price
Intrinsic Value
512 684.36 KRW
Overvaluation 71%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Cytek Biosciences Inc
NASDAQ:CTKB
4.36 USD
Samsung Biologics Co Ltd
KRX:207940
1 754 000 KRW
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
CTKB, 207940

CTKB
207940
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Cytek Biosciences Inc
Revenue
Samsung Biologics Co Ltd
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
CTKB, 207940

CTKB
207940
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Cytek Biosciences Inc
NASDAQ:CTKB
Samsung Biologics Co Ltd
KRX:207940
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

CTKB
53.5%
Samsung Biologics Co Ltd
56.3%

Operating Margin

CTKB
-16.2%
Samsung Biologics Co Ltd
36.6%

Net Margin

CTKB
-6.5%
Samsung Biologics Co Ltd
29%

FCF Margin

CTKB
-3%
Samsung Biologics Co Ltd
13.1%

ROE

CTKB
-3.3%
Samsung Biologics Co Ltd
14%

ROA

CTKB
-2.6%
Samsung Biologics Co Ltd
9.3%

ROIC

CTKB
-12.3%
Samsung Biologics Co Ltd
10.1%

ROCE

CTKB
-7.5%
Samsung Biologics Co Ltd
14.9%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
CTKB, 207940

Loading
CTKB
207940
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CTKB, 207940

Loading
CTKB
207940
Difference
www.alphaspread.com

Performance By Year
CTKB, 207940

Loading
CTKB
207940
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare CTKB to other stocks
0KHE
PerkinElmer Inc
P
More expensive
vs CTKB
TMO
Thermo Fisher Scientific...
Cheaper
vs CTKB
DHR
Danaher Corp
More expensive
vs CTKB
LONN
Lonza Group AG
Cheaper
vs CTKB
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett